AstraZeneca Pharma India surrenders marketing authorisation of prostate cancer drug

AstraZeneca Pharma India has voluntarily surrendered the marketing authorisation for its prostate cancer drug Olaparib (Lynparza) 100mg and 150mg in India, citing commercial reasons. The company clarified that the drug was never marketed in India since receiving approval in November 2023 and that the decision is unrelated to safety or efficacy concerns.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ql3ZY9T
via IFTTT